A Single Center, Phase 1, Single-Ascending Dose, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects
Latest Information Update: 05 Aug 2021
At a glance
- Drugs CoVIg-19 (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics; Pharmacokinetics; Registrational
- Sponsors CSL Behring
- 29 Jul 2021 Status changed from completed to discontinued.
- 14 Jul 2021 Status changed from active, no longer recruiting to completed.
- 19 May 2021 Planned End Date changed from 1 May 2021 to 1 Jun 2021.